These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37837491)

  • 1. Low-dimensional neural ODEs and their application in pharmacokinetics.
    Bräm DS; Nahum U; Schropp J; Pfister M; Koch G
    J Pharmacokinet Pharmacodyn; 2024 Apr; 51(2):123-140. PubMed ID: 37837491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
    Fleisher B; Brown AN; Ait-Oudhia S
    Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exact solutions and equi-dosing regimen regions for multi-dose pharmacokinetics models with transit compartments.
    Hof F; Bridge LJ
    J Pharmacokinet Pharmacodyn; 2021 Feb; 48(1):99-131. PubMed ID: 33040255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
    Ayyar VS; Jusko WJ
    Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compartmental modeling in the analysis of biological systems.
    Bassingthwaighte JB; Butterworth E; Jardine B; Raymond GM
    Methods Mol Biol; 2012; 929():391-438. PubMed ID: 23007439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological Indirect Response Model to Omics-Powered Quantitative Systems Pharmacology Model.
    Uatay A; Gall L; Irons L; Tewari SG; Zhu XS; Gibbs M; Kimko H
    J Pharm Sci; 2024 Jan; 113(1):11-21. PubMed ID: 37898164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural-ODE for pharmacokinetics modeling and its advantage to alternative machine learning models in predicting new dosing regimens.
    Lu J; Deng K; Zhang X; Liu G; Guan Y
    iScience; 2021 Jul; 24(7):102804. PubMed ID: 34308294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractional kinetics in multi-compartmental systems.
    Dokoumetzidis A; Magin R; Macheras P
    J Pharmacokinet Pharmacodyn; 2010 Oct; 37(5):507-24. PubMed ID: 20886267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Model to Describe Morphine Pharmacokinetics in Humans.
    Liu T; Ivaturi V; Gobburu J
    J Clin Pharmacol; 2019 Aug; 59(8):1070-1077. PubMed ID: 30840337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models.
    Valderrama D; Ponce-Bobadilla AV; Mensing S; Fröhlich H; Stodtmann S
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):41-53. PubMed ID: 37843389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.
    Buil-Bruna N; López-Picazo JM; Martín-Algarra S; Trocóniz IF
    Oncologist; 2016 Feb; 21(2):220-32. PubMed ID: 26668254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling.
    Chou WC; Lin Z
    Toxicol Sci; 2023 Jan; 191(1):1-14. PubMed ID: 36156156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of machine learning techniques to the analysis and prediction of drug pharmacokinetics.
    Ota R; Yamashita F
    J Control Release; 2022 Dec; 352():961-969. PubMed ID: 36370876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving from basic toward systems pharmacodynamic models.
    Jusko WJ
    J Pharm Sci; 2013 Sep; 102(9):2930-40. PubMed ID: 23681608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semiparametric mixed-effects analysis of PK/PD models using differential equations.
    Wang Y; Eskridge KM; Zhang S
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):443-63. PubMed ID: 18781382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and utilization of physiologically based pharmacokinetic models for toxicological applications.
    Leung HW
    J Toxicol Environ Health; 1991 Mar; 32(3):247-67. PubMed ID: 2002511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacometrics in pregnancy: An unmet need.
    Ke AB; Rostami-Hodjegan A; Zhao P; Unadkat JD
    Annu Rev Pharmacol Toxicol; 2014; 54():53-69. PubMed ID: 24392692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
    Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.